

1
2 ***Cross-sectional cycle threshold values reflect epidemic dynamics of COVID-19 in Madagascar***
3

4 **Authors and affiliations:**

5 Soa Fy Andriamandimby, Virology Unit, Institut Pasteur de Madagascar*
6 Cara E. Brook, Department of Ecology and Evolution, University of Chicago*
7 Norosoa Razanazato, Virology Unit, Institut Pasteur de Madagascar
8 Jean-Marius Rakotondramanga, Epidemiology and Clinical Research Unit, Institut Pasteur de
9 Madagascar
10 Fidisoa Rasambainarivo, Department of Ecology and Evolutionary Biology, Princeton
11 University
12 Vaomalala Raharimanga, Epidemiology and Clinical Research Unit, Institut Pasteur de
13 Madagascar
14 Iony Manitra Razanajatovo, Virology Unit, Institut Pasteur de Madagascar
15 Reziky Mangahasimbola, Epidemiology and Clinical Research Unit, Institut Pasteur de
16 Madagascar
17 Richter Razafindratsimandresy, Virology Unit, Institut Pasteur de Madagascar
18 Santatra Randrianarisoa, Department of Veterinary Sciences and Medicine, University of
19 Antananarivo
20 Barivola Bernardson, Epidemiology and Clinical Research Unit, Institut Pasteur de Madagascar
21 Joelinotahiana Hasina Rabarison, Virology Unit, Institut Pasteur de Madagascar
22 Mirella Randrianarisoa, Epidemiology and Clinical Research Unit, Institut Pasteur de Madagascar
23 Frédéric Stanley Nasolo, Virology Unit, Institut Pasteur de Madagascar
24 Roger Mario Rabetombo, Epidemiology and Clinical Research Unit, Institut Pasteur de
25 Madagascar
26 Rindra Rendremanana[#], Epidemiology and Clinical Research Unit, Institut Pasteur de
27 Madagascar
28 Jean-Michel Héraud^{††}, Virology Unit, Institut Pasteur of Dakar
29 Philippe Dussart[#], Virology Unit, Institut Pasteur de Madagascar
30

31 **Contact info for corresponding author:**

32 Soa Fy Andriamandimby, Virology Unit, Institut Pasteur de Madagascar, soafy@pasteur.mg

33 *Lead authors contributed equally.

34 [#]These senior authors contributed equally to this work.

35 [†]Present address: Virology Department, Institut Pasteur de Dakar.
36
37
38
39
40
41
42
43
44
45
46

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92

Abstract:

As the national reference laboratory for febrile illness in Madagascar, we processed samples from the first epidemic wave of COVID-19, between March and September 2020. We fit generalized additive models to cycle threshold (C_t) value data from our RT-qPCR platform, demonstrating a peak in high viral load, low- C_t value infections temporally coincident with peak epidemic growth rates estimated in real time from publicly-reported incidence data and retrospectively from our own laboratory testing data across three administrative regions. We additionally demonstrate a statistically significant effect of duration of time since infection onset on C_t value, suggesting that C_t value can be used as a biomarker of the stage at which an individual is sampled in the course of an infection trajectory. As an extension, the population-level C_t distribution at a given timepoint can be used to estimate population-level epidemiological dynamics. We illustrate this concept by adopting a recently-developed, nested modeling approach, embedding a within-host viral kinetics model within a population-level Susceptible-Exposed-Infectious-Recovered (SEIR) framework, to mechanistically estimate epidemic growth rates from cross-sectional C_t distributions across three regions in Madagascar. We find that C_t -derived epidemic growth estimates slightly precede those derived from incidence data across the first epidemic wave, suggesting delays in surveillance and case reporting. Our findings indicate that public reporting of C_t values could offer an important resource for epidemiological inference in low surveillance settings, enabling forecasts of impending incidence peaks in regions with limited case reporting.

Key Words: COVID-19, LMIC, Madagascar, Africa, cycle threshold value, cross-sectional data

93

94 **Introduction.**

95 Madagascar reported its first case of coronavirus disease 2019 (COVID-19) on 19 March
96 2020, in part with a government-sponsored surveillance platform testing all incoming
97 international travelers [1]. Subsequent to this introduction, the first wave of the COVID-19
98 epidemic was geographically staggered, with early cases in May 2020 largely concentrated in the
99 eastern city of Toamasina, part of the Atsinanana administrative region, followed by a more
100 severe outbreak which peaked in July 2020 in the capital city of Antananarivo, part of the
101 Analamanga administrative region. Test positive rates exceeded 50% at the epidemic peak for
102 both regions and at the national level, indicating widespread underreporting [2], a common
103 feature of COVID-19, for which some 20-40% of infections are thought to be entirely
104 asymptomatic [3–6]. Early reporting on the first epidemic wave in Madagascar indicated an
105 extremely high (56.6%) proportion of asymptomatic cases, based on targeted surveillance of
106 symptomatic patients and their contacts [1].

107 Madagascar closed its borders to international air travel on 20 March 2020 and,
108 subsequent to identification of the first case, implemented several non-pharmaceutical
109 interventions aimed at curbing epidemic spread, including non-essential business closures,
110 curfews, stay-at-home orders, and mandates for social distancing. These restrictions were relaxed
111 after the first epidemic subsided in September 2020 but have since been re-implemented in the
112 face of a second epidemic wave. In other regions of the globe, widespread efforts to estimate the
113 effective reproduction number, R_t , for COVID-19 at national, regional, and local levels [7] have
114 been used to inform public health interventions and retrospectively assess their effectiveness [8]:
115 disease transmission rates are increasing at $R_t > 1$ and decreasing at $R_t < 1$. Estimation of R_t , or
116 its related counterpart, r , the epidemic growth rate [9,10], from available case count data is
117 challenged by limitations or variability in surveillance, uncertainty surrounding the shape of
118 disease parameter distributions, and delays in reporting [8]. Despite the enormity of these
119 challenges in the limited surveillance settings common to many lower- and middle-income
120 countries (LMICs), real-time estimation of R_t from COVID-19 case-counts has been attempted
121 for most regions of the globe [7] and has been implemented locally in Madagascar [11].

122 Recent methodological advances have introduced a new resource to the epidemiological
123 toolkit by which to conduct real time estimation of epidemic trajectories [12], one that leverages
124 the often-discarded cycle threshold, or C_t , value, that is returned as an-inverse log-10 measure of
125 viral load from all RT-qPCR-based platforms [13]. After observing that SARS-CoV-2 viral
126 loads—and, as a consequence RT-qPCR C_t values—demonstrate a predictable trajectory
127 following the onset of infection [14–16], Hay et al. 2020 showed that the C_t value can be used as
128 a biomarker of time since infection and, consequently, be leveraged to back-calculate infection
129 incidence, in a manner analogous to previous work leveraging serological titer information in
130 other systems [17–19]. Probabilistically, a randomly-selected infection is more likely to be early
131 in its infection trajectory when identified during a growing epidemic and later in its trajectory in
132 a declining epidemic [20,21], and as a consequence, the population-level distribution of C_t values
133 for any viral infection is expected to shift across the duration of an epidemic. Indeed, low- C_t -
134 high-viral-load infections have been observed to coincide with growing COVID-19 epidemics
135 and high- C_t -low-viral-load infections with declining epidemics in several settings [15,22,23].
136 Exploiting this phenomenon, Hay et al. 2020 developed a method that embeds a within-host,
137 viral kinetics model in a population-level disease transmission model to derive epidemic
138 trajectories from cross-sectional C_t samples. Because this method depends on quantitative

139 information captured in the biological sample itself, rather than the relationship between case
140 count and reporting date, C_t value estimation more accurately predicts true epidemic trajectories
141 than traditional incidence estimation in settings with uneven surveillance [12].

142 During the early phase of the COVID-19 epidemic in Madagascar, the Virology Unit
143 laboratory (National Influenza Centre) at the Institut Pasteur of Madagascar (IPM) processed the
144 majority of all SARS-CoV-2 testing samples derived from 114 districts across 6 major provinces
145 in the country. Consistent with findings reported elsewhere [15,22,23], we observed a
146 population-level decline in C_t values derived from RT-qPCR-testing in our laboratory, coincident
147 with the epidemic peak across the first wave of COVID-19 in Madagascar. We here adopt the
148 methods presented by Hay et al. 2020 to estimate COVID-19 epidemic growth rates at the
149 national level (2018 population ~26 million [24]) and in two major administrative regions of
150 Madagascar: Atsinanana (east coast of Madagascar; 2018 population ~1.5 million [24]) and
151 Analamanga (including Antananarivo, capital city; 2018 population ~3.6 million [24]). These
152 two regions comprised the geographic epicenter of the first COVID-19 wave in Madagascar;
153 data from other regions were too sparse for epidemiological inference. We evaluate the
154 robustness of this C_t -based method in comparison with epidemic growth rates derived from more
155 traditional case-count methods applied to the same regions.

156 **Materials and Methods.**

157

158 *IPM SARS-CoV-2 C_t Data.*

159 Methods for collection, transport, and processing of SARS-CoV-2 testing samples at IPM
160 have been previously described [1]. Briefly, nasopharyngeal and oropharyngeal swabs were
161 collected at local administrative hospitals in viral transport medium and transported at 4°C to our
162 laboratory for testing. Between 18 March and 30 September 2020, we conducted 34,563 RT-
163 qPCR tests targeting the E, N, Orf1a/b, or S gene of SARS-CoV-2. These tests were carried out
164 across 20,326 discrete samples (many of which were tested across multiple platforms targeting
165 multiple genes), and 17,499 discrete patients, a subset of whom were tested at multiple
166 timepoints. The majority of tests were conducted on individuals who independently sought
167 testing, due to concerns about exposure or symptom presentation, though a subset of samples
168 were derived from efforts to trace and test contacts of positive travelers in the early stages of the
169 pandemic [1]. The reason each patient sought testing was not recorded in the original data.

170 Due to a dearth of available reagents in the early stages of the epidemic, our lab used
171 seven different WHO-recommended kits and corresponding protocols [25] to assay infection in
172 these samples [1]: Charity Berlin [26], Hong Kong University [27], Da An gene (Da An Gene
173 Co., Ltd. Sun Yatsen University, Guangzhou, China), LightMix® SarbeCoV E-gene plus EAV
174 control (TIB Biolmol, Berlin, Germany), SarbeCoV TibMolBiol (TIB Biolmol, Berlin,
175 Germany), TaqPath™ COVID- 19 Combo kit (Life Technologies Ltd, Paisley, UK), and
176 GeneXpert (Cepheid, Sunnyvale, CA, USA).

177 Some 9,493 of those tests, corresponding to 5,310 individuals, were RT-qPCR positive
178 for SARS-CoV-2 infection based on the cut-off positive value for the test in question (Charity
179 Berlin: ≤ 38 ; Hong Kong: ≤ 40 ; Da An: ≤ 40 ; LightMix SarbeCoV/SarbeCoV TibMolBiol \leq
180 38 ; TaqPath ≤ 37 for 2 of 3 targets; GeneXpert = ≤ 40). All analyses presented in this paper
181 are derived from these positive test results, as C_t -values were not reliably recorded following
182 negative results. We further subset our data as appropriate for each analysis of interest.


183

184

185
186
187
188
189
190
191
192
193
194
195
196
197
198
199

Estimating growth rates from IPM case data.

We first sought to obtain an estimate of new daily cases reported from our laboratory to the Malagasy government between 18 March and 30 September 2020. To this end, we reduced our dataset to include only sampling from the first reported positive test date for each unique patient; we assumed that reinfection was unlikely within the short duration of our study and that any subsequent positive tests were reflective of longer-duration infections in repeatedly sampled individuals. A patient was considered “positive” for SARS-CoV-2 infection if any test for any SARS-CoV-2 target was positive, and the results of the other samples were not inconsistent with this finding. We then summed cases by date at the national level and for two administrative regions (Atsinanana and Analamanga) that reported the majority of total cases across the study period overall. In total, 5,276 cases were reported from our laboratory across the study period at the national level, 3,505 in Analamanga region and 758 in Atsinanana. Daily cases for the two target regions and for the nation at large are summarized in Fig. 1.



200
201
202
203
204
205
206
207
208

Fig. 1. Epidemic growth rate estimates from case count data across the first wave of COVID-19 in Madagascar. (A.) Map of Madagascar, colored by regions of case count tabulation, showing the Atsinanana region (orange), the Analamanga region (green), and the National region (blue); note that data analyzed at the National level includes data from both Atsinanana and Analamanga regions, as well as the rest of Madagascar. (B.) Time series of new case incidence (lefthand y-axis) across the first wave of COVID-19 in Madagascar (18 March – 30 September 2020), across three focal regions. Darker shading shows data derived from the IPM RT-qPCR platform, while lighter shading depicts data nationally reported and consolidated on [11]. Righthand y-axis shows corresponding epidemic growth rate computed from case count data in EpiNow2 [28], with darker line

209 corresponding to computation from IPM data and lighter line to computation from publicly reported data;
210 background shading around each line depicts the corresponding 50% quantile by EpiNow2 [28].
211

212 We applied the opensource R-package EpiNow2 [28] to the daily incidence data to
213 estimate the epidemic growth rate for COVID-19 across the study period. EpiNow2 builds on
214 previous R_t estimation packages [29], using a non-stationary Gaussian process model to estimate
215 the instantaneous time-varying reproduction number, R_t , and the corresponding time-varying
216 epidemic growth rate, r , while incorporating uncertainty in the generation interval. Following
217 best recommended practices [8], we modeled the SARS-CoV-2 incubation period as a log-
218 normal distribution with a mean of 1.621 days (sd=0.064) and a standard deviation of 0.418 days
219 (sd=0.061) [30] and the generation time interval as a gamma distribution with a mean of 3.635
220 (sd=0.71) and a standard deviation of 3.075 (0.77) [31]. Since the IPM testing data reported the
221 actual date of sample collection, no reporting delay was incorporated in our growth rate
222 estimation.
223

224 *Epidemic trajectories from publicly reported data.*

225 To compare our laboratory-derived epidemic growth estimates with those undertaken in
226 real time in Madagascar, we collaborated with colleagues who recorded data on the number of
227 new PCR-confirmed cases reported daily on national television by the Ministry of Health of the
228 Government of Madagascar across the duration of the first epidemic wave. From these daily case
229 estimates, we used the EpiNow2 package [28] to again estimate the epidemic growth rate across
230 the same study period, assuming the same incubation period and general time interval referenced
231 above [30,31]. For these estimates, we followed methods outlined in [32], to additionally model
232 a reporting delay from a log-normal distribution fit to 100 subsamples with 1000 bootstraps from
233 a publicly available linelist that collates data globally for COVID-19 cases for which both
234 infection onset and notification dates are available [33].
235

236 *Standardizing C_t values across tests and targets.*

237 In our next series of analyses, we leveraged information captured in the individual C_t
238 value returned from each positive test. To control for extensive variation in qPCR test and target
239 (each of which reported varying thresholds for positivity), we carried out *in vitro* experiments
240 using SARS-CoV-2 isolates from infected patients reporting similar C_t values on the TaqPath
241 platform at the time of sampling. Briefly, three SARS-CoV-2 isolates (designated hCoV-
242 19/Madagascar/IPM-00754/2021, hCoV-19/Madagascar/IPM-01263/2021 and hCoV-
243 19/Madagascar/IPM-01315/2021) were obtained and cultured in Vero cells as previously
244 described [34]. Upon infection with SARS-CoV-2, the culture medium was replaced by infection
245 medium containing DMEM, 5 % FBS, antibiotics, 2.5 $\mu\text{g/ml}$ Amphotericin B (Gibco) and 16
246 $\mu\text{g/ml}$ TPCK-trypsin (Gibco). Virus-containing supernatants, as determined by the presence of
247 cytopathic effect (CPE), were harvested 7 days after infection by centrifugation at 1500 r.p.m.
248 for 10 min. RNA was subsequently extracted from supernatant and subjected to serial dilutions
249 and subsequent testing on six of the seven RT-qPCR platforms used in our population-level
250 dataset (LightMix SarbeCoV and SarbeCoV TibMolBiol were considered equivalent and tested
251 only using the current version of the kit: SarbeCoV TibMolBiol). We fit linear mixed effect
252 regression models in the lme4 [35] package in R to the resulting C_t curves returned from each
253 testing platform across the dilution series and used the fitted slope and y-intercept of each
254 regression equation to reproject all C_t values in our dataset to correspond to results returned from

255 the TaqPath N gene test. We report, analyze, and visualize these TaqPath N corrected C_t values
256 in all analyses.

257

258 *Generalized additive modeling of the longitudinal C_t distribution by region.*

259 After observing a population-level dip in the average C_t value recovered from our testing
260 platform, roughly coincident with the epidemic peak in the three regions of interest, we asked the
261 broad question, *what is the population level time-trend of SARS-CoV-2 C_t values across these*
262 *three regions?* To address this question, we compiled all positive tests from the first date of
263 positive testing for each patient, recording the date, region, test, and target that corresponded to
264 each corrected C_t value, in addition to the numerical ID and the symptom status (asymptomatic,
265 symptomatic, or unknown) of the patient from which it was derived. Symptom statuses were
266 recorded by medical staff at the timepoint of sampling and merely indicated whether or not the
267 patient presented with symptoms; thus, ‘asymptomatic’ classification did exclude the possibility
268 that the same patient reported symptoms at later or earlier timepoints across the course of
269 infection. The resulting data consisted of 8,055 discrete C_t values, corresponding to 5,280
270 patients, most of whom were tested using multiple tests and/or gene targets of interest. C_t values
271 for these positive test results ranged from 6.36 to 39.91. When reprojected to TaqPath N levels,
272 the range shifted from 7.82 to 39.99, such that 507 C_t values classed as “positive” by the cutoff
273 thresholds on other platforms exceeded the $C_t \leq 37$ threshold for positivity on the TaqPath
274 platform. These samples were nonetheless retained for generalized additive modeling (GAM) of
275 longitudinal C_t trends but GAM-projected C_t values still exceeding the TaqPath cutoff were later
276 excluded in mechanistic modeling of transmission trends fitted to positive data.

277 Using the `mgcv` package [36] in the R statistical program, we next fit a GAM in the
278 gaussian family to the response variable of corrected C_t value, incorporating a numerical
279 thinplate smoothing predictor of date, and random effects on the categorical variables of test
280 (Charity Berlin, Hong Kong, Da An, LightMix SarbeCoV, SarbeCoV TibMolBio, TaqPath, or
281 GeneXpert), target (E,N,Orf1a/b, or S), and individual patient ID. We refit the model to three
282 different subsets of the data, encompassing the Atsinanana and Analamanga regions, as well as
283 the entire National data as a whole. We then used the resulting fitted GAMs to simulate
284 population-level C_t distributions for each date in our dataset, excluding the effects of test and
285 target in the `predict.gam` function from `mgcv`. This produced a test- and target-controlled average
286 C_t estimate for each positive patient at the timepoint of sampling. We used these GAM-simulated
287 C_t distributions to carry out mechanistic model fitting in subsequent analyses, as described
288 below, excluding 15 patients with C_t projections >37 , which exceeded the positive threshold for
289 the TaqPath N gene assay (our standard).

290

291 *Generalized additive modeling of C_t value since time of infection onset.*

292 To validate observations from the literature which indicate that the viral load and
293 corresponding C_t value follow a predictable trajectory after the onset of SARS-CoV-2 infection
294 [14,15] within our own study system, we next concentrated analyses on a subset of 4,822 C_t
295 values (corresponding to 2,842 unique samples derived from 2,404 unique patients), for which
296 the timing of symptom onset was also recorded. For each of these samples, we randomly drew a
297 corresponding incubation time from the literature-derived log-normal distribution above [30] to
298 approximate the timing of infection onset. To answer the question, *how does C_t vary with time*
299 *since symptom onset?*, we fit a GAM in the gaussian family to the resulting data with a response
300 variable of C_t and a numerical thinplate smoothing predictor of days since infection onset, as

301 well as random effects of test, target, and patient ID. After fitting, we used the `predict.gam`
302 function from the `mgcv` package, excluding the effects of target and test, to produce a
303 distribution of C_t values corresponding to times since symptom onset (one per each unique
304 patient ID). We used these C_t trajectories to estimate parameters for the within-host viral kinetics
305 model described in final methods section below.

306
307 *Generalized additive modeling of the relationship between C_t value and symptom status.*

308 We next asked the question, *does C_t value vary in symptomatic vs. asymptomatic cases?*
309 Our first investigation of this question required only reconsideration of the individual trajectory
310 GAM described above to include additional predictor variables of age and symptom status, in
311 addition to days since infection onset, target, and test. Since symptom status was recorded only at
312 the first timepoint of sampling for each individual, we limited our individual trajectory dataset to
313 a 4,072 datapoint subset of C_t values from 2,404 discrete patients reporting both date of
314 symptom/infection onset and symptom status at the timepoint of sampling; as mentioned
315 previously, ‘asymptomatic’ classification in our dataset included patients reporting symptoms
316 from earlier or later timepoints prior to or following the sampling date. Thus, this GAM tested
317 whether symptom status and C_t value interacted merely as a function of the timing since
318 symptom onset (e.g. high C_t values were recovered from patients either very early or late in their
319 infection trajectory), or whether independent interactions between symptomatic vs.
320 asymptomatic infections and C_t were also present, while also controlling for age.

321 After observing results, we extended this analysis by applying another GAM in the
322 gaussian family to a 7,937 datapoint subset of the data used to model longitudinal C_t trajectories
323 at the National level, which additionally reported symptom status (symptomatic vs.
324 asymptomatic) at the timepoint of first sampling for 5,202 unique patients. Corrected C_t values in
325 this data subset ranged between 7.82 and 39.99. This GAM incorporated a response variable of
326 C_t and random effects predictor smoothing terms of symptom status, test, target, and patient ID,
327 as well as a numerical smoothing predictor for age of the infected patient.

328
329 *Estimating epidemic growth rates from cross-sectional C_t values.*

330 Finally, following newly-developed methods [12], we sought to estimate the epidemic
331 growth rate across our three regions of interest using cross-sectional C_t distributions and compare
332 these results against estimates derived from case count methods described above. To this end, we
333 first fit the within-host viral kinetics model described in Hay et al. 2020 to the test- and target-
334 controlled C_t values produced from the above GAM describing C_t as a function of time since
335 infection. We used the resulting parameter estimates as informed priors (Table S1) which we
336 next incorporated into two population-level SARS-CoV-2 transmission models applied to our
337 time series data across the three Madagascar regions: a compartmental SEIR model and a more
338 flexible Gaussian process model [12]. Beyond the viral kinetics parameters, we adopted less-
339 constrained priors from the original paper [12] for other epidemiological parameters included in
340 both population-level models (Table S1), then re-fit both transmission models in turn to cross-
341 sectional weekly C_t distributions derived from the Atsinanana, Analamanga, and National-level
342 datasets. We fit both models to each dataset using an MCMC algorithm derived from `lazymcmc`
343 R-package [37], as described in the original paper [12], applying the default algorithm to the
344 Gaussian process fit and a parallel tempering algorithm able to accurately parse multimodal
345 posterior distributions to the SEIR fit. Four MCMC chains were run for 500,000 iterations in the
346 case of the Gaussian process model and three MCMC chains for 80,000 iterations each in the

347 case of the SEIR model, then evaluated for convergence via manual inspection of the resulting
348 trace plots and verification that \hat{R} , the potential scale reduction factor, had a value <1.1 and the
349 effective population size had a value >200 for all parameters estimated.

350 After confirming chain convergence, we computed epidemic growth rates from the
351 resulting estimated infection time series and compared results with those derived using more
352 traditional case count methods outlined above. Code and supporting datasets needed to reproduce
353 all analyses are available for download on our opensource GitHub repository at:
354 github.com/carabrook/Mada-Ct-Distribute.

355

356 **Results.**

357 *Epidemic trajectories from case count data.*

358 The first wave of COVID-19 infections in Madagascar, between March and September
359 2020, was characterized by two subsequent outbreaks: one early, May 2020 peak centered in the
360 eastern port city of Toamasina (region Atsinanana), followed by a second peak in July centered
361 in the capital city of Antananarivo (region Analamanga) (Fig. 1) [1]. Estimation of the epidemic
362 growth rate showed broad agreement in trends at both the national and regional levels, whether
363 computed from IPM testing data assuming perfect reporting of testing date, or from publicly
364 reported national data, including a reporting delay parameterized from a global opensource
365 database (Fig. 1) [33]. Since IPM data comprised just over 30% of nationally reported data
366 throughout the first six months of the Madagascar epidemic, this concurrence in growth rates
367 was unsurprising but nonetheless validates the applicability of the globally parameterized
368 reporting delay for use in Madagascar. In both datasets, we estimated the national level epidemic
369 growth rate to be increasing in the months preceding the two epidemic sub-peaks (in April and in
370 June) and declining beginning in mid-July after the last peak in national case counts (Fig. 1).
371 When IPM data were considered at the regional level, we discovered the April peak to be
372 concentrated in Atsinanana, preceding the Toamasina outbreak and the June peak to be
373 concentrated in Analamanga preceding the Antananarivo outbreak. Growth rate estimation from
374 publicly reported data confirmed this pattern for Analamanga but was not possible for the
375 Atsinanana region due to a lack of clarity in regional reporting.

376

377 *Standardizing C_t values across tests and targets.*


378 All RT-qPCR platforms used in our laboratory demonstrated increases in C_t value
379 corresponding to 10-fold dilutions of RNA extracted from the original virus isolate (Table S2),
380 though the estimated slope and y-intercept of each regression varied across the tests and targets
381 considered, with the steepest slope recovered from GeneXpert N-gene tests and the shallowest
382 from the Hong Kong ORF1a/b kits (Fig. S1, Table S3). We used the corresponding slope and y-
383 intercept for each test and platform to transform C_t values in all subsequent analyses into values
384 predicted for a TaqPath N-gene platform.

385

386 *Longitudinal population-level trends in SARS-CoV-2 C_t values across the epidemic wave.*

387 We observed a population-level dip in C_t values obtained from our SARS-CoV-2 RT-
388 qPCR platform concurrent with the regional peak in cases in May for Atsinanana and June for
389 Analamanga, with both peaks observable in the National data (Fig. 2A). GAMs fit to Atsinanana,
390 Analamanga, and National data subsets explained, respectively, 98.8, 98.9, and 98.9% of the
391 deviation in the data (Table S4). All three GAMs demonstrated statistically significant effects of
392 date, test, and individual patient ID, which contributed to the total deviance capture by each

393 model. GAMs fit to the Analamanga and National data subsets showed an additional significant
 394 effect of target on the C_t value. Partial effects plots were computed from the resulting GAMs
 395 (Fig. S2) following methods described in [38] and demonstrated no significant effects of any
 396 particular test or target gene. In general, most variation in C_t value beyond that of the individual
 397 patient was driven by the significant effect of date across all regions (Table S4).
 398



399 **Fig. 2. RT-qPCR SARS-CoV-2 C_t value as a biomarker of population-level epidemic pace and individual**
 400 **infection trajectory.** (A.) Population-level SARS-CoV-2 corrected C_t values from IPM RT-qPCR platform across
 401 three Madagascar regions from March-September 2020. C_t values are colored by the test and shaped by the target
 402 from which they were derived (legend), though note that all C_t values were first corrected to TaqPath N gene range.
 403 Black trend line gives the output from a gaussian GAM fit to these data (Table S4), excluding the effects of target
 404 and test, which were also included as predictors in the model; 95% confidence intervals by standard error are shown
 405 in translucent shading. Partial effects of each predictor are visualized in Fig. S2. Righthand plots visualize partial
 406 effects of (B.) days since infection, (C.) patient age, and (D.) patient symptom status on C_t value from our individual
 407 trajectory GAM (Table S5). Significant predictors are depicted in light blue and non-significant in gray (Table S5).
 408
 409

410 *Individual trends in SARS-CoV-2 C_t values across the trajectory of infection.*

411 The SARS-CoV-2 C_t value also demonstrated a predictable trajectory from the timing of
 412 onset of infection. Our GAM fit to data reporting a date of symptom onset (which we converted
 413 to a date of infection onset) and incorporating a predictor smoothing term of days since infection
 414 onset, and random effects of test, target, and patient ID explained 92.7% of the deviance in the
 415 data and demonstrated statistically significant effects of all predictor variables, including days
 416 since infection onset (Table S5). These findings confirmed that C_t value can be used as a
 417 biomarker of time since infection, validating the applicability of methods outlined in [12] for our
 418 Madagascar data.

419

420 *Relationship between symptom status and SARS-CoV-2 C_t value.*

421 As an extension of the individual trajectory analysis, we hypothesized that C_t value
422 would likely be linked to symptom status, since many infection trajectories begin with a brief
423 presymptomatic phase, progress to symptom presentation, then become asymptomatic during
424 recovery [14,15]. The first GAM we employed to address this question considered age and
425 symptom status as additional predictor variables in our individual trajectory analysis. This final
426 GAM explained 98.5% of the deviation in the data and included significant effects of days since
427 infection onset, symptom status, test, target, and patient ID (Table S5). Despite the significance
428 of symptom status as a predictor variable in the GAM overall, partial effects plots demonstrated
429 no significant association between asymptomatic status and high C_t values or symptomatic status
430 and low C_t values, while controlling for age (Fig. 2B, 2C, 2D). These results suggest that, in our
431 dataset, C_t value varies predictably with an individual's infection trajectory regardless of
432 symptom classification or age of the patient, further validating its adoption as a robust biomarker
433 of time since infection (Table S5).

434 We additionally extended this analysis to our National-level C_t dataset, including a
435 predictor variable of symptom status, in addition to test, target, patient age, and patient ID in
436 longitudinal GAMs. This model explained 98.9% of the deviation witnessed in the data,
437 including significant effects of test, target, patient ID, and symptom status (Table S6). Test and
438 target were here included as control variates only and cannot be considered for prediction, as
439 both co-varied with date, which was not used as a predictor in this model. In this model, partial
440 effects plots indicated a significant association of asymptomatic status with high C_t values and
441 symptomatic status with low C_t values (Fig. S3), even when controlling for effects of age; as this
442 larger dataset did not report date of symptom/infection onset, it is likely that this association co-
443 varied with the timing of infection onset, suggesting that previous reports of a high proportion of
444 asymptomatic infections in Madagascar [1] could reflect a high proportion of pre- or post-
445 symptomatic infections.


446

447 *Epidemiological dynamics inferred from cross-sectional C_t distributions.*

448 After confirming the predictable pattern of C_t value across an individual's infection
449 trajectory, and the predictable decline in population-level C_t in conjunction with the epidemic
450 peak, we used our individual trajectory GAM to simulate a distribution of C_t values across a 50-
451 day duration of infection and fit the within-host viral kinetics model described in [12] to the
452 resulting data (Fig. S4). The model demonstrated a good fit to the data, and estimated posterior
453 distributions for viral kinetics parameters were largely on par with those used previously in
454 models of SARS-CoV-2 dynamics in Massachusetts, though the modal C_t value at peak viral
455 load was slightly lower in our Madagascar dataset (Fig S4; Table S1).

456 After fitting the within-host model, we next used longitudinal population-level GAMs
457 (Fig. S2) to generate weekly cross-sectional C_t distributions, controlled for test and target, across
458 our three regions of interest. As expected, weekly cross-sectional C_t distributions demonstrated a
459 shift across the duration of the epidemic wave; with lower C_t values temporally correlated with
460 high growth rates estimated from case count data (Fig. 3).


461



462
 463 **Fig. 3. Population-level C_t distribution reflects epidemic dynamics of the first wave of COVID-19 across three**
 464 **Madagascar regions. (A.)** Simulated weekly C_t distributions by Madagascar region, derived from population-level
 465 longitudinal GAMs (Fig. 2A), excluding random effects of test and target. **(B.)** Higher skew and lower median C_t
 466 from each cross-sectional C_t distribution in (A.) were loosely associated with higher epidemic growth rates from the
 467 corresponding week, here derived from EpiNow2 estimation from IPM case count data (Fig. 1B.) **(C.)** Cross-
 468 sectional C_t distributions from Analamanga time series in (A.) were fit via Gaussian process (GP) and SEIR
 469 mechanistic models incorporating a within-host viral kinetics model. Modeled C_t distributions are shown as solid
 470 lines (GP=red; SEIR=purple), with 95% quantiles in surrounding sheer shading. Both models effectively recapture
 471 the shape of the C_t histogram as it changes (skews left) across the duration of the first epidemic wave. Model fits to
 472 the full time series of C_t histograms across all three regions are visualized in Fig. S7, S8, S9.

473
 474 Finally, we used the viral kinetics posterior distributions resulting from the within-host
 475 viral kinetics model fit as prior inputs into SEIR and Gaussian process population-level
 476 epidemiological models, which we fit to the weekly cross-sectional C_t data. MCMC chains
 477 generated in the fitting process demonstrated good convergence (Fig. S5, Table S7, Table S8)
 478 and produced posterior distributions for all parameters on par with those estimated in previous
 479 work (Table S1, Fig. S6), which effectively recaptured cross-sectional C_t value histograms across
 480 the target timeseries in all three regions (Fig. 3, Fig. S7-S9) [12]. From the resulting fitted
 481 models, we simulated epidemic incidence curves, which we used to compute growth rate
 482 estimates across the duration of the first epidemic wave in each of the three regions (Fig. 4). We
 483 compared these estimates to growth rates inferred from case count data; patterns from both SEIR
 484 and Gaussian process models were largely complementary, though the more flexible Gaussian
 485 process model demonstrated less extreme variation in epidemic growth rate. Both C_t -model fits
 486 demonstrated similar patterns to epidemic trajectories estimated from incidence data, with
 487 increasing growth rates in the months preceding both epidemic sub-peaks (April and June) and
 488 decreasing growth rates beginning in July. Nonetheless, growth rate estimates derived from the
 489 C_t model slightly preceded those estimated from case count data. The C_t model fits further
 490 predicted uncertainty in growth rate directionality towards the end of the study period for the

491 Analamanga and National-level data, while incidence estimation projected decreasing cases at
 492 this time. This finding suggests that cross-sectional C_t distributions indicated a possible epidemic
 493 resurgence which was overlooked by growth rates estimated from declining incidence. If
 494 incidence declined in part due to declining surveillance, as was the reality at the end of
 495 Madagascar's first epidemic wave [1], only the C_t method remained robust to the possibility of
 496 epidemic renewal.



497 **Fig. 4. Epidemic growth rate estimates from mechanistic model fits to population-level C_t distributions across**
 498 **the first wave of COVID-19 in three Madagascar regions. (A.)** Comparison of COVID-19 epidemic growth rates
 499 from March-September 2020, estimated from IPM (blue) and publicly reported (gray) case count data using
 500 EpiNow2 [28] with estimates derived from Gaussian process (GP; red) mechanistic model fit to the time series of C_t
 501 distributions (Fig. 3A). Median growth rates are shown as solid lines, with 50% quantile on case-based estimates
 502 and 95% quantile of the posterior distributions from C_t -based estimates in corresponding sheer shading. (B.) Growth
 503 rate estimates from individual SEIR C_t -model fits to each C_t -distribution shown in Fig. 3A; median growth rates are
 504 given as horizontal dashes, with the 95, 70, 50, and 20% of the posterior distribution indicated by progressively
 505 darker coloring. Estimates >0 (indicating growing epidemics) are depicted in gold and <0 (indicating declining
 506 epidemics) in purples. (C.) Raw case count data from the time series (dark=IPM data; light=publicly reported data)
 507 is shown for reference.
 508

509
 510 **Conclusions.**

511 Real-time estimation of epidemiological parameters, including the time-varying effective
 512 reproduction number, R_t , and the related instantaneous epidemic growth rate, r , has played an
 513 important role in guiding public health interventions and policies across many epidemic
 514 outbreaks, including COVID-19 [39–41]. In Madagascar, an opensource platform [11] was
 515 developed shortly after the introduction of COVID-19 in March 2020, to collate and visualize
 516 publicly reported data and estimate R_t using traditional methods applied to daily reported
 517 incidence [28,29]. We here compare the results from this platform applied to the first epidemic
 518 wave in Madagascar, with new estimates of the time-varying epidemic growth rate applied to our

519 own laboratory data across the first epidemic wave—including those derived using a novel
520 method based on the cross-sectional C_t value distribution at the time of sampling [12].

521 We find our new estimates to be largely congruent with those predicted from publicly
522 reported data, demonstrating a pattern of increasing epidemic growth rates prior to a peak in
523 cases, which occurred first in May 2020 in the Atsinanana region, followed by a second outbreak
524 in July 2020 in the Analamanga region. Critically, our growth rate estimates derived using novel
525 methods applied to the C_t distribution over time slightly precede those estimated from incidence
526 data. As previous work has demonstrated C_t estimation to offer a more robust approximation of
527 true dynamics under limited surveillance scenarios [12], these findings suggest that incidence-
528 based methods to estimate epidemic trajectories in Madagascar may be underestimating the true
529 pace of the epidemic, likely as a result of underreporting. Additionally, C_t -based methods
530 adopted by a single laboratory allow for estimation of epidemic growth rates even in the absence
531 of publicly reported case counts: in October 2020, the Malagasy Ministry of Health shifted its
532 daily COVID-19 case notifications to weekly, interfering with incidence-based approaches to
533 estimate epidemic trajectories [11]. C_t -based approaches, instead, should be robust to this
534 variation in reporting, offering a powerful tool for public health efforts in low surveillance
535 settings. Indeed, our analysis demonstrates that C_t -based epidemic growth rates show uncertain
536 directionality towards the end of the first wave of COVID-19 in Madagascar, presaging eventual
537 epidemic resurgence, while incidence-based rates categorically declined due to both truly
538 declining cases and declining surveillance. Incidence-based growth rate estimation ceased during
539 the continued limited surveillance period from October 2020 through March 2021 [11]; had C_t -
540 based methods been available at the time, it is possible that the current second wave could have
541 been predicted and mitigated by earlier rollout of public health interventions.

542 Statistical analysis of our C_t data indicates that C_t values vary predictably with days since
543 onset of infection, allowing viral kinetics data to be leveraged for population-level estimation of
544 epidemiological patterns. In our system, this pattern held even after controlling for the effects of
545 age and symptom status on the C_t trajectory, further validating the applicability of C_t value as an
546 indicator of time since infection. Nonetheless, in future work, it may be possible to fit unique
547 viral kinetics trajectories for different classes of people; for example, older age cohorts or
548 cohorts of people infected with more transmissible variants may be better represented by lower
549 average C_t trajectories than the population as a whole [15,42]. Our application of generalized
550 additive models to both individual infection trajectory and population-level C_t distributions
551 offers an effective means by which to control for variation in test and target across diverse RT-
552 qPCR platforms to generate C_t values for epidemiological inference which represent a reliable
553 average of population-level patterns overall.

554 We acknowledge the limitations of our current method, especially as it relates to testing
555 biases. During the earliest phases of the epidemic in Madagascar, testing resources were limited
556 in our laboratory, which may have biased sample intake towards high-viral-load, low- C_t -value
557 cases that could bias epidemiological inference towards increasing growth rates even after the
558 epidemic has, in reality, already begun to decline. As the epidemic ensued, however, the
559 Madagascar Ministry of Health focused sampling on symptomatic patients and their suspected
560 contacts, leading to a high proportion (56.6%) of reported asymptomatic infections in our dataset
561 [1], which may have instead prematurely biased inference towards a declining epidemic.
562 Nonetheless, our C_t -based projections of epidemic trajectories do not appear to underestimate
563 realized trends, suggesting that our method was robust to these inconsistencies.

564 We apply a novel method leveraging within-host viral load data that is currently largely
565 overlooked in the epidemiological literature to describe the dynamics of the first wave of
566 COVID-19 in Madagascar. Our approach validates an important new tool for epidemiological
567 inference of ongoing epidemics, particularly applicable to limited surveillance settings
568 characteristic of many lower- and middle- income countries. We advocate for public release of
569 real time data describing the C_t value distribution, in addition to daily case counts, to improve
570 epidemiological inference to guide public health response and intervention.

571
572

573 **Acknowledgements**

574 This work was supported by the US National Institutes of Health [1R01AI29822-01]; the Bill &
575 Melinda Gates Foundation, Seattle, WA [GCE OPP1211841]; and the Innovative Genomics
576 Institute at UC Berkeley, Berkeley, CA [COVID-19 Rapid Response Grant]. The authors thank
577 Malavika Rajeev, Tanjona Ramiadantsoa, and Benjamin Rice for help in establishing the
578 Madagascar COVID-19 dashboard.

579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609

610 References

- 611
- 612 [1] R. Randremanana, S. Andriamandimby, J.M. Rakotondramanga, N. Razanajatovo, R.
613 Mangahasimbola, T. Randriambolamanantsoa, H. Ranaivoson, H. Rabemananjara, I.
614 Razanajatovo, J. Rabarison, C. Brook, F. Rakotomanana, R. Rabetombosoa, H.
615 Razafimanjato, V. Ahyong, V. Raharinosy, V. Raharimanga, S. Raharinantoanina, M.
616 Randrianarisoa, B. Bernardson, L. Randrianasolo, Z. Randriamanantany, J. Heraud, C.Z.
617 Biohub, The COVID-19 Epidemic in Madagascar: clinical description and laboratory
618 results of the first wave, March-September 2020, *Influenza Other Respi. Viruses*. 00
619 (2021) 1–12.
- 620 [2] M.H. Chitwood, M. Russi, K. Gunasekera, J. Havumaki, V.E. Pitzer, J.L. Warren, D.M.
621 Weinberger, T. Cohen, N.A. Menzies, Menzies3, Bayesian nowcasting with adjustment
622 for delayed and incomplete reporting to estimate COVID-19 infections in the United
623 States, *MedRxiv*. 20 (2020) 1–6. doi:10.18907/jjsre.20.7_624_5.
- 624 [3] D.P. Oran, E.J. Topol, Prevalence of asymptomatic SARS-CoV-2 infection: A narrative
625 review, *Ann. Intern. Med.* 173 (2020) 362–367. doi:10.7326/M20-3012.
- 626 [4] K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic
627 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess
628 cruise ship, Yokohama, Japan, 2020, *Eurosurveillance*. 25 (2020) 1–5. doi:10.2807/1560-
629 7917.ES.2020.25.10.2000180.
- 630 [5] H. Nishiura, T. Kobayashi, T. Miyama, A. Suzuki, S. mok Jung, K. Hayashi, R. Kinoshita,
631 Y. Yang, B. Yuan, A.R. Akhmetzhanov, N.M. Linton, Estimation of the asymptomatic
632 ratio of novel coronavirus infections (COVID-19), *Int. J. Infect. Dis.* 94 (2020) 154–155.
633 doi:10.1016/j.ijid.2020.03.020.
- 634 [6] T.A. Treibel, C. Manisty, M. Burton, Á. McKnight, J. Lambourne, J.B. Augusto, X.
635 Couto-Parada, T. Cutino-Moguel, M. Noursadeghi, J.C. Moon, COVID-19: PCR
636 screening of asymptomatic health-care workers at London hospital, *Lancet*. 395 (2020)
637 1608–1610. doi:10.1016/S0140-6736(20)31100-4.
- 638 [7] S. Abbott, J. Hellewell, R.N. Thompson, K. Sherratt, H.P. Gibbs, N.I. Bosse, J.D.
639 Munday, S. Meakin, E.L. Doughty, J.Y. Chun, Y.-W.D. Chan, F. Finger, P. Campbell, A.
640 Endo, C.A.B. Pearson, A. Gimma, T. Russell, C.C. modelling Group, S. Flasche, A.J.
641 Kucharski, R.M. Eggo, S. Funk, Temporal variation in transmission during the COVID-19
642 outbreak, (n.d.).
- 643 [8] K.M. Gostic, L. McGough, E.B. Baskerville, S. Abbott, K. Joshi, C. Tedijanto, R. Kahn,
644 R. Niehus, A. Hay, P.M. De Salazar, J. Hellewell, S. Meakin, J.D. Munday, N.I. Bosse, K.
645 Sherrat, R.N. Thompson, L.F. White, J.S. Huisman, J. Scire, S. Bonhoeffer, T. Stadler, J.
646 Wallinga, S. Funk, M. Lipsitch, S. Cobey, Practical considerations for measuring the
647 effective reproductive number, *Rt*, *PLoS Comput. Biol.* 16 (2020) e1008409.
648 doi:10.1371/journal.pcbi.1008409.
- 649 [9] J. Wallinga, M. Lipsitch, How generation intervals shape the relationship between growth
650 rates and reproductive numbers, *Proc. R. Soc. B-Biological Sci.* 274 (2007) 599–604.
651 doi:10.1098/rspb.2006.3754.
- 652 [10] S.W. Park, B.M. Bolker, D. Champredon, D.J.D. Earn, M. Li, J.S. Weitz, B.T. Grenfell, J.
653 Dushoff, Reconciling early-outbreak estimates of the basic reproductive number and its
654 uncertainty : framework and applications to the novel coronavirus (SARS-CoV-2)
655 outbreak, *J. R. Soc. Interface*. 17 (2020) 20200144.

- 656 [11] F. Rasambainarivo, T. Ramiadantsoa, S. Randrianarisoa, M. Rajeev, B. Rice, C.J. Metcalf,
657 COVID-19 Madagascar Dashboard, (2020).
- 658 [12] J.A. Hay, L. Kennedy-Shaffer, S. Kanjilal, N.J. Lennon, S.B. Gabriel, M. Lipsitch, M.J.
659 Mina, Estimating epidemiologic dynamics from cross-sectional viral load distributions,
660 MedRxiv. (2021).
- 661 [13] M.R. Tom, M.J. Mina, To interpret the SARS-CoV-2 test, consider the cycle threshold
662 value, *Clin. Infect. Dis.* 71 (2020) 2252–2254. doi:10.1093/cid/ciaa619.
- 663 [14] Y. Chen, L. Li, SARS-CoV-2: virus dynamics and host response, *Lancet Infect. Dis.* 2019
664 (2020) 2019–2020. doi:10.1016/S1473-3099(20)30235-8.
- 665 [15] D. Jacot, G. Greub, K. Jatou, O. Oputa, Viral load of SARS-CoV-2 across patients and
666 compared to other respiratory viruses, *Microbes Infect.* 22 (2020) 617–621.
667 doi:10.1016/j.micinf.2020.08.004.
- 668 [16] B. Borremans, A. Gamble, K.C. Prager, S.K. Helman, A.M. McClain, C. Cox, V. Savage,
669 J.O. Lloyd-Smith, Quantifying antibody kinetics and rna detection during early-phase
670 SARS-CoV-2 infection by time since symptom onset, *Elife.* 9 (2020) 1–27.
671 doi:10.7554/ELIFE.60122.
- 672 [17] B. Borremans, N. Hens, P. Beutels, H. Leirs, J. Reijnders, Estimating time of infection
673 using prior serological and individual information can greatly improve incidence
674 estimation of human and wildlife infections, *PLoS Comput. Biol.* 12 (2016) e1004882.
675 doi:10.1371/journal.pcbi.1004882.
- 676 [18] J.A. Hay, A. Minter, K.E.C. Ainslie, J. Lessler, B. Yang, D.A.T. Cummings, A.J.
677 Kucharski, S. Riley, An open source tool to infer epidemiological and immunological
678 dynamics from serological data: Serosolver, *PLoS Comput. Biol.* 16 (2020) 1–24.
679 doi:10.1371/journal.pcbi.1007840.
- 680 [19] H. Salje, D.A.T. Cummings, I. Rodriguez-barrquer, L.C. Katzelnick, J. Lessler, C.
681 Klungthong, B. Thaisomboonsuk, A. Nisalak, A. Weg, D. Ellison, L. Macareo,
682 Reconstruction of antibody dynamics and infection histories to evaluate dengue risk,
683 *Nature.* 557 (2018) 719–723. <http://dx.doi.org/10.1038/s41586-018-0157-4>.
- 684 [20] J. Wallinga, M. Lipsitch, How generation intervals shape the relationship between growth
685 rates and reproductive numbers, *Proc. R. Soc. B Biol. Sci.* 274 (2007) 599–604.
686 doi:10.1098/rspb.2006.3754.
- 687 [21] G. Rydevik, G.T. Innocent, G. Marion, R.S. Davidson, P.C.L. White, C. Billinis, P.
688 Barrow, P.P.C. Mertens, D. Gavrier-Widén, M.R. Hutchings, Using Combined Diagnostic
689 Test Results to Hindcast Trends of Infection from Cross-Sectional Data, *PLoS Comput.*
690 *Biol.* 12 (2016) 1–19. doi:10.1371/journal.pcbi.1004901.
- 691 [22] M. Moraz, D. Jacot, M. Papadimitriou-Olivgeris, L. Senn, G. Greub, K. Jatou, O. Oputa,
692 Universal admission screening strategy for COVID-19 highlighted the clinical importance
693 of reporting SARS-CoV-2 viral loads, *New Microbes New Infect.* 38 (2020) 100820.
694 doi:10.1016/j.nmni.2020.100820.
- 695 [23] A.S. Walker, E. Pritchard, T. House, J. V Robotham, P.J. Birrell, J.I. Bell, J.N. Newton, J.
696 Farrar, I. Diamond, R. Studley, J. Hay, Viral load in community SARS-CoV-2 cases
697 varies widely and temporally, (2020).
- 698 [24] I.N. de la S. Madagascar., Troisieme Recensement General de la Population et de
699 L’Habitation (RGPH-3) Resultats Provisoires, 2018.
- 700 [25] The World Health Organization (WHO). Molecular assays to diagnose COVID-19:
701 Summary table of available protocols 2020, (n.d.). <https://www.who.int/publi%20catio>

- 702 ns/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols.
703 [26] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K.W. Chu, T. Bleicker,
704 S. Brünink, J. Schneider, M.L. Schmidt, D.G.J.C. Mulders, B.L. Haagmans, B. Van Der
705 Veer, S. Van Den Brink, L. Wijsman, G. Goderski, J.L. Romette, J. Ellis, M. Zambon, M.
706 Peiris, H. Goossens, C. Reusken, M.P.G. Koopmans, C. Drosten, Detection of 2019 novel
707 coronavirus (2019-nCoV) by real-time RT-PCR, *Eurosurveillance*. 25 (2020).
708 doi:10.2807/1560-7917.ES.2020.25.3.2000045.
- 709 [27] D.K.W. Chu, Y. Pan, S.M.S. Cheng, K.P.Y. Hui, P. Krishnan, Y. Liu, D.Y.M. Ng, C.K.C.
710 Wan, P. Yang, Q. Wang, M. Peiris, L.L.M. Poon, Molecular diagnosis of a novel
711 coronavirus (2019-nCoV) causing an outbreak of pneumonia, *Clin. Chem.* 66 (2020) 549–
712 555. doi:10.1093/clinchem/hvaa029.
- 713 [28] S. Abbott, J. Hellewell, K. Sherratt, K. Gostic, J. Hickson, H.S. Badr, M. DeWitt, R.
714 Thompson, EpiForecasts, S. Funk, EpiNow2: Estimate real-time case counts and time-
715 varying epidemiological parameters, (2020).
- 716 [29] A. Cori, N.M. Ferguson, C. Fraser, S. Cauchemez, A new framework and software to
717 estimate time-varying reproduction numbers during epidemics, *Am. J. Epidemiol.* 178
718 (2013) 1505–1512. doi:10.1093/aje/kwt133.
- 719 [30] S.A. Lauer, K.H. Grantz, Q. Bi, F.K. Jones, Q. Zheng, H.R. Meredith, A.S. Azman, N.G.
720 Reich, J. Lessler, The incubation period of coronavirus disease 2019 (CoVID-19) from
721 publicly reported confirmed cases: Estimation and application, *Ann. Intern. Med.* 172
722 (2020) 577–582. doi:10.7326/M20-0504.
- 723 [31] T. Ganyani, C. Kremer, D. Chen, A. Torneri, C. Faes, J. Wallinga, N. Hens, Estimating
724 the generation interval for coronavirus disease (COVID-19) based on symptom onset data,
725 March 2020, *Eurosurveillance*. 25 (2020) 1–8. doi:10.2807/1560-
726 7917.ES.2020.25.17.2000257.
- 727 [32] S. Abbott, J. Hellewell, R.N. Thompson, K. Sherratt, H.P. Gibbs, N.I. Bosse, J.D.
728 Munday, S. Meakin, E.L. Doughty, J.Y. Chun, Y.D. Chan, F. Finger, P. Campbell, A.
729 Endo, C.A.B. Pearson, A. Gimma, T. Russell, C. Covid, S. Flasche, A.J. Kucharski, R.M.
730 Eggo, S. Funk, Estimating the time-varying reproduction number of SARS-CoV-2 using
731 national and subnational case counts, *Wellcome Open Res.* (2021) 1–10.
- 732 [33] B. Xu, B. Gutierrez, S. Mekaru, K. Sewalk, L. Goodwin, A. Loskill, E.L. Cohn, Y.
733 Hswen, S.C. Hill, M.M. Cobo, A.E. Zarebski, S. Li, C.H. Wu, E. Hulland, J.D. Morgan, L.
734 Wang, K. O'Brien, S.V. V. Scarpino, J.S. Brownstein, O.G. Pybus, D.M. Pigott, M.U.G.
735 Kraemer, Epidemiological data from the COVID-19 outbreak, real-time case information,
736 *Sci. Data*. 7 (2020) 1–6. doi:10.1038/s41597-020-0448-0.
- 737 [34] H. Auerswald, S. Yann, S. Dul, S. In, P. Dussart, N.J. Martin, E.A. Karlsson, J.A. Garcia-
738 Rivera, Assessment of inactivation procedures for SARS-CoV-2, *J. Gen. Virol.* 102
739 (2021) 1–5. doi:10.1099/JGV.0.001539.
- 740 [35] D. Bates, M. Mächler, B.M. Bolker, S.C. Walker, Fitting linear mixed-effects models
741 using lme4, *J. Stat. Softw.* 67 (2015) 1–48. doi:10.18637/jss.v067.i01.
- 742 [36] S.N. Wood, mgcv: GAMs and Generalized Ridge Regression for R, *R News*. 1/2 (2001)
743 20–24.
- 744 [37] J. Hay, lazycmc, (2020). <https://github.com/jameshay218/lazycmc>.
- 745 [38] N. Mollentze, D.G. Streicker, Viral zoonotic risk is homogenous among taxonomic orders
746 of mammalian and avian reservoir hosts, *Proc. Natl. Acad. Sci.* (2020) 1–8.
747 doi:10.1073/pnas.1919176117.

748 [39] S. Cauchemez, P.Y. Boëlle, C.A. Donnelly, N.M. Ferguson, G. Thomas, G.M. Leung, A.J.
749 Hedley, R.M. Anderson, A.J. Valleron, Real-time estimates in early detection of SARS,
750 *Emerg. Infect. Dis.* 12 (2006) 110–113. doi:10.3201/eid1201.050593.

751 [40] A.J. Kucharski, T.W. Russell, C. Diamond, Y. Liu, J. Edmunds, S. Funk, R.M. Eggo, F.
752 Sun, M. Jit, J.D. Munday, N. Davies, A. Gimma, K. van Zandvoort, H. Gibbs, J.
753 Hellewell, C.I. Jarvis, S. Clifford, B.J. Quilty, N.I. Bosse, S. Abbott, P. Klepac, S.
754 Flasche, Early dynamics of transmission and control of COVID-19: a mathematical
755 modelling study, *Lancet Infect. Dis.* 20 (2020) 553–558. doi:10.1016/S1473-
756 3099(20)30144-4.

757 [41] A. Pan, L. Liu, C. Wang, H. Guo, X. Hao, Q. Wang, J. Huang, N. He, H. Yu, X. Lin, S.
758 Wei, T. Wu, Association of public health interventions with the epidemiology of the
759 COVID-19 outbreak in Wuhan, China, *JAMA - J. Am. Med. Assoc.* 323 (2020) 1915–
760 1923. doi:10.1001/jama.2020.6130.


761 [42] M. Kidd, A. Richter, A. Best, N. Cumley, J. Mirza, B. Percival, M. Mayhew, O. Megram,
762 F. Ashford, T. White, E. Moles-Garcia, L. Crawford, A. Bosworth, S.F. Atabani, T. Plant,
763 A. McNally, S-Variant SARS-CoV-2 lineage B.1.1.7 is associated with significantly
764 higher viral load in samples tested by TaqPath Polymerase Chain Reaction, *J. Infect. Dis.*
765 223 (2021). doi:10.1093/infdis/jiab082.

766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793

794 **Supplementary Figures.**

795

796



797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812


813

814

815


816

Fig. S1. Ct-dilution curves of RT-qPCR tests in tissue culture. RNA isolates from three patients positive with comparable Ct values for SARS-CoV-2 infection underwent serial dilutions (x-axis) RT-qPCR assay (y-axis) across six RT-qPCR platforms used in our laboratory during the first wave of the COVID-19 epidemic (Table S2). We fit linear mixed effect regression models in the lme4 R package [35] to the resulting dilution series across multiple runs and replicates (shapes, colors) for each isolation to establish a trend line (lines and equations). We used the resulting slope and y-intercept (Table S3) to standardize all Ct values in our dataset in terms of TaqPath N-gene assays for downstream analysis.




817
 818 **Fig. S2. Partial effects of test, target, and date on SARS-CoV-2 Ct values across three**
 819 **Madagascar regions.** Partial effects of GAMs fitted to longitudinal C_t data from (A.,B.,C.)
 820 Atsinanana region, (D.,E.,F.) Analamanga region and (G.,H.,I.) National data. Model outputs
 821 are summarized in Table S4 and visualized in Fig. 2A. (main text). Significant partial effects
 822 determined by holding all other variables constant (see [38] for methods) are depicted in blue
 823 and insignificant partial effects in gray. Columns demonstrated relative effects of RT-qPCR test
 824 (A.,D.,G.), target gene (B.,E.,H), and date (C.,F.,I.). Note that patient ID was also included in
 825 each model as a (significant) random effect.

826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836




837
838 **Fig. S3. Partial effects of age and symptom status from population-level GAM.** Partial
839 effects of GAM fitted to national Ct data with response variable of correct C_t and predictor
840 smoothing terms of test, target, and patient ID (as random effect controls) as well as (A.) age and
841 (B.) symptom status. Model outputs are summarized in Table S6. Significance is indicated by
842 blue shading: the significant effect of symptom status on Ct is likely the result of time since
843 onset of infection (i.e. ‘asymptomatic’ patients were either very early or very late in their
844 infection trajectory), which was not specified in these data.
845
846
847




848
 849 **Fig. S4. Fitting the within-host viral kinetics model to Madagascar data.** Figure recapitulates
 850 Fig. S2 from [12] for our Madagascar data. The thick blue line in (A.) gives the fitted viral load
 851 trajectory for the Madagascar data output from the individual trajectory GAM summarized in
 852 Table S5 but excluding the effect of test and PCR-target. Madagascar data are shown as
 853 translucent colors in the background. Thin blue lines surrounding the thick line are trajectories
 854 from prior draws within the 95% quantile, and violin plots show the distribution of detectable Ct
 855 values post infection inferred from the fitted trajectory (blue line). As in [12], violins are colored
 856 by the proportion of Ct values above the limit of PCR detection (10³ RNA cp/μl). Panel (B.)
 857 shows the least-squares based fit (colored line) to the proportion of patients with detectable
 858 SARS-CoV-2 in upper respiratory tract samples on each day post symptom onset from
 859 Borremans et al. [16]. As in [12], black dots and lines show proportion positive and 95%
 860 confidence intervals. Faint grey lines show proportion detectable over time from prior draws, and
 861 faint grey ribbon shows 95% quantiles. Panel (C.) gives the assumed prior densities for viral
 862 kinetics model parameters fit to Madagascar data (Table S1).

863
 864




865
 866 **Fig. S5. Example trace plots for MCMC-fit of Gaussian process and SEIR Ct-models.** Trace
 867 plots returned from MCMC fitting of (A.) Gaussian process (4-chains, standard MCMC) and (B.)
 868 mechanistic SEIR models (3 chains, parallel tempering MCMC) to Madagascar National-level
 869 time series of Ct distributions. Traces in (B.) show results from fitting to timepoint 77, the Ct
 870 distribution from the week of April 27, 2020. Parameter details are given in Table S1. All traces
 871 show good convergence, but as in [12], we observed that SEIR models demonstrated clear multi-
 872 modality in some parameter distributions, chiefly R_0 and t_0 . Data can be explained by either high
 873 R_0 and low t_0 or low R_0 and high t_0 .


874
 875
 876
 877
 878




879
 880 **Fig. S6. Posterior distributions for fitted SEIR and Gaussian process models to**
 881 **Madagascar Ct timeseries.** Posterior distributions for all parameters inferred from MCMC
 882 fitting for (A.) Gaussian process (4-chains, standard MCMC) and (B.) mechanistic SEIR models
 883 (3 chains, parallel tempering MCMC) to Madagascar National-level time series of Ct
 884 distributions. Parameter details are given in Table S1. As in Fig. S5, distributions in (B.) show
 885 results from fitting to timepoint 77, the Ct distribution from the week of April 27, 2020.
 886 Multimodality in R_0 and t_0 is also evident here: data can be explained by either high R_0 and low t_0
 887 or low R_0 and high t_0 .
 888
 889
 890
 891
 892



893
894 **Fig. S7. Gaussian process and SEIR Ct-model fits to cross-sectional histograms of Ct values**
895 **across the Atsinanana time series.** Extension of Fig. 3C (main text) depicts the weekly
896 histogram of Ct values from the National timeseries in blue, and the resulting Ct distributions at
897 each timepoint from fitted Gaussian process (red) and SEIR (purple) models. Thick line gives the
898 median of distribution for each fit and translucent shading corresponds to the 95% quantiles.
899
900
901
902
903
904
905
906
907
908
909
910



911
912 **Fig. S8. Gaussian process and SEIR Ct-model fits to cross-sectional histograms of Ct values**
913 **across the Analamanga time series.** Extension of Fig. 3C (main text) depicts the weekly
914 histogram of Ct values from the Analamang timeseries in green, and the resulting Ct
915 distributions at each timepoint from fitted Gaussian process (red) and SEIR (purple) models.
916 Thick line gives the median of distribution for each fit and translucent shading corresponds to the
917 95% quantiles.



918
 919 **Fig. S9. Gaussian process and SEIR Ct-model fits to cross-sectional histograms of Ct values**
 920 **across the Atsinanana time series.** Extension of Fig. 3C (main text) depicts the weekly
 921 histogram of Ct values from the Atsinanana timeseries in red, and the resulting Ct distributions at
 922 each timepoint from fitted Gaussian process (red) and SEIR (purple) models. Thick line gives the
 923 median of distribution for each fit and translucent shading corresponds to the 95% quantiles.
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935

936 **Supplementary Table Captions.**

937

938 **Table S1. Model parameters (for viral kinetics + SEIR + Gaussian process models).** Fixed
939 and estimated parameters and corresponding descriptions for all parameters used in viral
940 kinetics, SEIR, and Gaussian process models fit to cross-sectional C_t distributions across all three
941 regions.

942

943 **Table S2. Dilution series of C_t value returned from disparate RT-qPCR platforms**
944 **inoculated with three virus isolates.** Raw data from tissue culture inoculations, showing C_t
945 value resulting from RNA extracted after virus isolate inoculations in cell culture. Data are
946 organized by the test and target used to assay each replicate of each isolate across the dilution
947 series.

948

949 **Table S3. Fitted linear mixed effect regression models to tissue culture inoculations in**
950 **Table S2.** Slopes and y-intercepts of linear mixed effects regression models fit to tissue culture
951 dilutions series in Table S2. Regression lines are visualized in Fig. S1; note that the predictor
952 variable of “dilution”, a proxy for viral load, is modeled on a log₁₀ scale.

953

954 **Table S4. Summary output from longitudinal C_t GAMs (Fig. 2D) by region.** Summary from
955 longitudinal GAMs fit to variation in population-level C_t across all three regions (Atsinanana,
956 A., Analamanga, B., National, C.) by date.

957

958 **Table S5. Summary output from individual trajectory GAMs.** Summary from individual
959 trajectory GAM used to parameterize within-host viral kinetics model (A.) and individual
960 trajectory GAM used to query the effect of symptom status on C_t variation independent of date
961 of infection onset (B.).

962

963 **Table S6. Summary output from population-level symptom status GAM.** Summary from
964 population-level GAM used to query the effect of symptom status on C_t variation across all
965 regions, independent of date.

966

967 **Table S7. Convergence diagnostics and posterior quantiles for Gaussian process- C_t models.**
968 Convergence diagnostics, including \hat{R} , the potential scale reduction factor (values <1.1) and
969 effective population size (values > 200) for all parameters estimated across all three regions via
970 Gaussian process model fit to C_t time series. Table also includes mean and 95% posterior
971 quantile for each parameter estimate from the fitted model.

972

973 **Table S8. Convergence diagnostics and posterior quantiles for SEIR- C_t models.**
974 Convergence diagnostics, including \hat{R} , the potential scale reduction factor (values <1.1) and
975 effective population size (values > 200) for all parameters estimated across all three regions at all
976 timepoints via mechanistic SEIR model fit to C_t time series. Table also includes mean and 95%
977 posterior quantile for each parameter estimate from the fitted model.

978